{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:49:07Z","timestamp":1753890547412,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Antimalarial resistance to the first-line partner drug piperaquine (PPQ) threatens the effectiveness of artemisinin-based combination therapy. <jats:italic>In vitro<\/jats:italic> piperaquine resistance is characterized by incomplete growth inhibition, i.e. increased parasite growth at higher drug concentrations. However, the 50% inhibitory concentrations (IC<jats:sub>50<\/jats:sub>) remain relatively stable across parasite lines. Measuring parasite viability of a drug-resistant Cambodian <jats:italic>Plasmodium falciparum<\/jats:italic> isolate in a parasite reduction ratio (PRR) assay helped to better understand the resistance phenotype towards PPQ. In this parasite isolate, incomplete growth inhibition translated to only a 2.5-fold increase in IC<jats:sub>50<\/jats:sub> but a dramatic decrease of parasite killing in the PRR assay. Hence, this pilot study reveals the potential of <jats:italic>in vitro<\/jats:italic> parasite viability assays as an important, additional tool when it comes to guiding decision-making in preclinical drug development and post approval. To the best of our knowledge, this is the first time that a compound was tested against a drug-resistant parasite in the <jats:italic>in vitro<\/jats:italic> PRR assay.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1396786","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:06:26Z","timestamp":1714453586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Incomplete Plasmodium falciparum growth inhibition following piperaquine treatment translates into increased parasite viability in the in vitro parasite reduction ratio assay"],"prefix":"10.3389","volume":"14","author":[{"given":"Annabelle","family":"Walz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Sax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balint","family":"Tamasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"M\u00e4ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Wittlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a novel mutation in the plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity","volume":"216","author":"Agrawal","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","article-title":"Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study","volume":"17","author":"Amato","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1126\/science.aax4735","article-title":"A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites","volume":"367","author":"Birnbaum","year":"2020","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41467-018-04104-z","article-title":"Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum","volume":"9","author":"Bopp","year":"2018","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: A probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J. Stat. Software"},{"key":"B7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12936-016-1569-y","article-title":"Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand","volume":"15","author":"Chaorattanakawee","year":"2016","journal-title":"Malar J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/AAC.03265-14","article-title":"Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strains","volume":"59","author":"Chugh","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1128\/mBio.00303-17","article-title":"A variant pfCRT isoform can contribute to plasmodium falciparum resistance to the first-line partner drug piperaquine","volume":"8","author":"Dhingra","year":"2017","journal-title":"mBio"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","article-title":"Plasmodium falciparum resistance to piperaquine driven by PfCRT","volume":"19","author":"Dhingra","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/1475-2875-11-292","article-title":"A framework for assessing the risk of resistance for anti-malarials in development","volume":"11","author":"Ding","year":"2012","journal-title":"Malar J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.pt.2021.04.006","article-title":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","volume":"37","author":"Duffey","year":"2021","journal-title":"Trends Parasitol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","article-title":"Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations","volume":"13","author":"Duru","year":"2015","journal-title":"BMC Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011436","article-title":"PfCRT mutations conferring piperaquine resistance in falciparum malaria shape the kinetics of quinoline drug binding and transport","volume":"19","author":"Gomez","year":"2023","journal-title":"PloS Pathog."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1128\/AAC.00481-15","article-title":"How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance","volume":"59","author":"Hastings","year":"2015","journal-title":"Antimicrobial Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","article-title":"A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites","volume":"55","author":"Huber","year":"1993","journal-title":"Acta Tropica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.06.543862","article-title":"A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II\/III to piperaquine drug resistance","author":"Kane","year":"2023","journal-title":"bioRxiv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00686-12","article-title":"Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010","volume":"57","author":"Leang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1021\/acs.jmedchem.8b01333","article-title":"Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains","volume":"61","author":"Le Manach","year":"2018","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1128\/AAC.00687-13","article-title":"Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers","volume":"57","author":"Lim","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(22)00294-8","article-title":"Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study","volume":"22","author":"Radohery","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e00114","DOI":"10.1128\/aac.00114-22","article-title":"Parasite viability as a measure of in vivo drug activity in preclinical and early clinical antimalarial drug assessment","volume":"66","author":"Radohery","year":"2022","journal-title":"Antimicrobial Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/infdis\/jiaa678","article-title":"Parasite viability as a superior measure of antimalarial drug activity in humans","volume":"223","author":"Rebelo","year":"2020","journal-title":"J. Infect. Diseases"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030949","article-title":"P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action","volume":"7","author":"Sanz","year":"2012","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.02302-15","article-title":"Atovaquone-Proguanil Remains a Potential Stopgap Therapy for Multidrug-Resistant Plasmodium falciparum in Areas along the Thai-Cambodian Border","volume":"60","author":"Saunders","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","article-title":"Dihydroartemisinin-piperaquine failure in Cambodia","volume":"371","author":"Saunders","year":"2014","journal-title":"N Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.exppara.2006.09.016","article-title":"In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models","volume":"115","author":"Snyder","year":"2007","journal-title":"Exp. Parasitol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1086\/656476","article-title":"Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure","volume":"202","author":"Teuscher","year":"2010","journal-title":"J. Infect. Diseases"},{"key":"B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/ph16020163","article-title":"The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro","volume":"16","author":"Walz","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12936-019-3056-8","article-title":"Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay","volume":"18","author":"Walz","year":"2019","journal-title":"Malaria J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/1475-2875-10-278","article-title":"The parasite clearance curve","volume":"10","author":"White","year":"2011","journal-title":"Malaria J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0055622","DOI":"10.1128\/aac.00556-22","article-title":"New in vitro interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations","volume":"66","author":"Wicha","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect. Diseases"},{"key":"B35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1128\/AAC.01636-09","article-title":"Increased tolerance to artemisinin in plasmodium falciparum is mediated by a quiescence mechanism","volume":"54","author":"Witkowski","year":"2010","journal-title":"Antimicrobial Agents Chemother."},{"volume-title":"WHO Guidelines for malaria","year":"2022","key":"B37"},{"volume-title":"World malaria report 2023","year":"2023","key":"B38"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1396786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:06:31Z","timestamp":1714453591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1396786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":38,"alternative-id":["10.3389\/fcimb.2024.1396786"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1396786","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"article-number":"1396786"}}